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Low-dose aspirin therapy in dogs inconsistently inhibits platelet function, termed
‘aspirin resistance’. There are no established diagnostic tests that can predict aspirin
resistance in dogs prior to therapy. Platelet function was evaluated in healthy dogs prior
to and during low-dose aspirin therapy using turbidimetric and impedance aggregometry,
PFA-100, and urine 11-dehydro-thromboxane-B2 concentration. Following a washout,
platelet-rich plasma from the dogs was incubated with aspirin and evaluated via
turbidimetric aggregometry. After aspirin, the majority of dogs were classified as
‘aspirin responders’ with 81% responding after 7 days. Platelet dysfunction was not
consistent in all dogs at all times. Compared to turbidimetric, impedance and PFA-100
results were inconsistent when run concurrently, suggesting turbidimetric is the preferred
technique. There was poor agreement between in vitro aspirin incubation and all other
tests. Unlike in people, platelet function in dogs is consistently inhibited by aspirin
incubation, making this a poor technique for predicting aspirin resistance.
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CHAPTER I
INTRODUCTION

Platelet formation and function
Platelet formation (thrombopoiesis) occurs mainly in bone marrow within the
megakaryocyte cell line. Megakaryocytes will mature and develop cytoplasmic
processes (proplatelets), and both megakaryocytes and proplatelets will undergo a
fragmentation process that results in shedding of platelets into the circulation.1-3 After
entering the circulation, the normal circulating lifespan of a platelet is about 5-7 days. 4
Platelets play an essential role in blood hemostasis, a process involving
interactions between vascular endothelium, coagulation factors, and other cell types.
Hemostasis is divided into three phases: primary hemostasis, secondary hemostasis, and
fibrinolysis. Primary hemostasis describes the interactions between platelets and vascular
endothelium that lead to the formation of a platelet plug. This platelet plug acts as the
first defense against hemorrhage, but is stable for only a short time and must be
reinforced. Secondary hemostasis is characterized by the coagulation cascade and
transformation of the platelet plug into a true blood clot through cross-linking of a fibrin
meshwork. The third phase is fibrinolysis, in which plasmin is activated to break down
fibrin and remove the blood clot. Alterations in the normal function of these phases can
create ineffective hemostasis which can lead to inappropriate or excessive clot formation
or bleeding.
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Circulating platelets are inactive and travel along the periphery of blood vessels
until they become exposed to damaged vascular endothelium.5 Platelets will then
become activated and adhere to the site of injury. Activation of platelets involves a
process by which platelets change shape, release the contents of their granules, and
express receptors on their surface that help to facilitate further aggregation. Once
activated, platelets release vasoactive substances that lead to vasoconstriction, decreased
blood flow, and blood stasis.6 The decreased blood velocity and narrowed vascular
lumen allow for increased contact time between platelets, damaged endothelium, and
coagulation factors, and promote the generation of a platelet plug and then a blood clot.
Adhesion and aggregation of platelets is further affected by shear conditions. Shear
describes the frictional forces exerted on the endothelial layer of the vessel wall by blood
flow.7 Shear varies by size and type of vessel with high shear thought to occur mainly in
small and medium sized arteries and low shear in larges arteries as well as veins.8 In
conditions of low shear, platelet adhesion to the endothelium occurs via collagen,
fibronectin, and laminin.5,9-11 Under high shear conditions, platelet adhesion is mediated
by collagen and von Willebrand factor (vWF).12 vWF is stored in the alpha granules of
platelets and Weibel-Palade bodies in endothelial cells.12 It helps platelets not only
adhere to the endothelium, but also to other platelets, thus enhancing aggregation. vWF
also acts to as a carrier protein and protector of factor VIII.
Platelets have two different receptors for vWF on their surface. The first is
Integrin αIIbβ3 (previously GP IIb-IIIa complex) which after activation changes to allow
binding of fibrinogen.12,13 After endothelial injury, vWF adheres to exposed collagen and
releases factor VIII. Platelets will then begin a process of rolling along the vessel wall
2

that is initiated by the second vWF receptor, GP Ibα in the GP Ib-IX-V complex. The
loose attachments of vWF to the endothelium that occur during rolling are further
mediated by P-selectin present on the activated endothelium.14 After the activated
platelet attaches to the endothelial collagen it undergoes a shape change that exposes the
Integrin αIIbβ3 receptor.15 The platelets produce membrane glycoproteins that further
perpetuate the process of platelet recruitment and aggregation.16
Platelet aggregation occurs as two separate phases – primary and secondary
aggregation. Primary aggregation describes a reversible process by which platelets
develop direct interactions and undergo a shape change from a spherical to a stellate form
consisting of multiple pseudopods. If no further stimulus is received, these platelet
aggregates can potentially disperse. Once the stored contents of the alpha and dense
granules of the platelet are released, aggregation becomes irreversible and the following
wave of aggregation composes secondary aggregation.17 In order for shape change to
occur during primary aggregation, the agonist adenosine diphosphate (ADP) must be
present. ADP is released during platelet degranulation and through its binding to the
P2Y12 receptor it creates the shape change by activating phospholipase C and causing
calcium mobilization.17,18 Binding of ADP to its receptors and associated calcium
mobilization is a major mediator of full platelet aggregation.

18

Platelets release many substances that are involved in creating the initial
environment contributing to their activation, such as ADP, serotonin, and prostaglandins.
Under high shear conditions, ADP is the main promoter of platelet activation.19,20 One of
the main mediators of platelet activation under low shear conditions is the prostaglandin
thromboxane A2 (TXA2). TXA2 is synthesized by platelets through conversion of
3

arachidonic acid by the cyclooxygenase (COX) enzyme. After its release, TXA2 triggers
vasoconstriction, leads to recruitment and subsequent activation of additional platelets,
and enhances platelet aggregation. 21 Thromboxane A2 works immediately but for only a
short period of time (approximately 30 seconds). Thromboxane A2 is rapidly
metabolized into thromboxane B2, and then 11-dehydro-thromboxane B2 and 2,3-dinorthromboxane B2. These stable metabolites are ultimately eliminated in the urine. 22-24
Platelets, like other cells, do not store thromboxane A2, but instead synthesize it as
needed from arachidonic acid. Arachidonic acid is released from phospholipid
membranes via the enzymatic action of phospholipases. 25-27 Arachidonic acid is then
converted into prostaglandin H2 by COX-1 and 2, also known as prostaglandin Hsynthase-1 and 2, respectively. COX-1 enzyme activity ultimately leads to the
production of prostaglandins such as TXA2 and prostacyclin (prostaglandin I2).26,28
Prostacyclin does not originate from platelets; instead it is released from vascular
endothelium. Prostacyclin acts in opposition to thromboxane A2 in that it causes
vasodilation and inhibition of platelet aggregation.25,26,29 By working together, these two
prostaglandins keep hemostasis in a balanced state.
At least three isoforms of COX have been described in the dog. COX-1 is
expressed constitutively in most body systems, and has the function of maintaining
normal cell activities such as gastric mucosal health and protection and preservation of
renal blood flow.27,30 COX-3 is a splice variant of COX-1 and has similar functions to
COX-1 but less activity (approximately 20% of the activity of COX-1 ).31,32 COX-2 has
a more limited distribution than COX-1, and a much lower level of expression. COX-2 is
expressed in tissues such as the brain, thymus, kidneys and vascular endothelium, and
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cell types such as circulating monocytes, fibroblasts, and tissue macrophages.30,33,34
COX-2 is inducible, and levels can be increased through the action of inflammatory
cytokines, growth factors, and endotoxins.27,35,36
Until recently, it was believed that COX-1 was the only isoform expressed by
circulating platelets, therefore making COX-1 the primary mediator of platelet TXA2
production. COX-2 was the isoform believed to be in control of prostacyclin
production.25,26,34,37,38 Recent research, however, has demonstrated that both COX-1 and
2 isoforms are expressed in human and dog platelets, with higher levels of COX-2
expression seen with increased platelet turnover and associated with higher levels of
immature (reticulated) platelets.28,33,37,39 These findings suggest a role for COX-2 in
platelet function.30,37
The process of platelet activation involves complicated interactions between a
variety of agonists including, but not limited to, thromboxane A2. These agonists act to
stimulate and activate platelets, cause vasoconstriction, and attract and then activate other
platelets, with the ultimate goal of creating a platelet plug. Platelets are anucleate, and
therefore rely on agonists and other stimuli to reach a state of activation. In order to
facilitate activation, platelets contain stored granules ranging in size from 200-500 nm
that contain a variety of proteins that aid in platelet adhesion, promote cell-to-cell
interactions, and stimulate vascular repair.40,41 These granules are referred to as dense
(delta) granules and alpha-granules. Dense granules contain ADP, serotonin, and
epinephrine.41 Alpha-granules are the main secretory component of platelets, and contain
adhesion molecules such as von Willebrand factor, P-selectin, and fibronectin. Alphagranules also contain pro- and anti-angiogenic factors such as vascular endothelial
5

growth factor, as well as coagulation factors such as fibrinogen and factors V and VIII.
Different molecules are selectively packaged within different alpha-granule subsets, both
during platelet formation in the bone marrow and after uptake by circulating platelets.40-44
During platelet activation, these selectively packaged molecules are released from alphagranules depending on the specific receptor activated and the specific platelet agonist
involved.40,41,45
Contained within alpha-granules is the molecule P-selectin, a cell adhesion
molecule that mediates platelet and leukocyte aggregation. P-selectin also generates
procoagulant microparticles that contain active tissue factor and enhance fibrin
deposition.46,47 Through these properties, P-selectin is thought to enhance both platelet
aggregation and secondary hemostasis. Platelet P-selectin is found in higher
concentrations in dogs suffering from primary immune mediated hemolytic anemia, and
may contribute to the thromboembolic complications that develop in these patients.48
Platelets play a supporting role in the formation and stabilization of a true blood
clot. Alpha-granules release pro-coagulant factors (factors V, VIII, and fibrinogen) that
work with other coagulation factors to promote clot formation. Additionally, after
activation, platelets undergo a shape change that creates a larger surface area for
adherence to the endothelium as well as other platelets or cells. 49 Activated platelets
may also express receptors and ligands on their surfaces that assist in thrombin and fibrin
formation. In particular, aminophospholipid phosphatidylserine, which is found in the
inner leaflet of inactivated platelets, will move to the platelet surface after activation and
bind to prothrombin, accelerating the conversion of prothrombin to thrombin and the
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formation of a blood clot.50 The phosphatidylserine-rich platelet surface is able to
synthesize thrombin at a rate 300,000 times faster than the fluid phase of plasma.50
Aspirin resistance
Unfortunately, treatment with low-dose aspirin does not consistently inhibit
platelet function in all dogs and, despite preventative therapy, some dogs treated with
aspirin will continue to develop thromboembolic complications. Previous research has
demonstrated that only about one-third of normal dogs treated with low-dose aspirin
respond to low-dose aspirin as expected, with prolongation in closure times as measured
on an in-house platelet function analyzer (PFA-100®), while the majority of dogs either
incompletely or inconsistently respond to the same dose of aspirin.39 A similar
phenomenon occurs in humans treated with low doses of aspirin, and people that are
poorly responsive to the anti-platelet effects of aspirin are termed ‘aspirin resistant’.62
The exact incidence of aspirin resistance in people is unknown, but the published
incidence ranges from 8 to 45% of human patients.56,62-64 Since canine clinic patients
appear to inconsistently respond to low-dose aspirin in terms of prevention of
thromboembolism, it is possible that, similar to humans, dogs also experience clinically
relevant aspirin resistance. The exact incidence of aspirin resistance in canine clinic
patients remains unknown.
The precise mechanism for aspirin resistance in both humans and dogs is
unknown, but several possible mechanisms have been proposed. These mechanisms can
be divided into ‘true’ aspirin resistance and unproven aspirin resistance. Causes of true
aspirin resistance include decreased bioavailability of aspirin, increased platelet turnover
to expand the pool of non-aspirinated platelets,65 competition with other nonsteroidal
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anti-inflammatory drugs (NSAIDs), 66 alternative pathways for the formation of
TXA2,37,67 the presence of variants of COX-1 which are less sensitive to aspirin
inhibition68, or poor compliance by the individual patient.69 Unproven causes of aspirin
resistance in people include increased sensitivity to ADP-induced activation of the
platelet surface membrane glycoprotein (GP) IIb/IIIa, polymorphisms in GPIIb/IIIa,
increased resistance to the platelet agonist collagen, high plasma von Willebrand factor
concentrations, and the proaggregatory activities of isoprostanes, hyperlipidemia,
smoking, and stress.70-75
One of the proposed mechanisms of aspirin resistance is the presence of an
alternate source of thromboxane A2.28 As aspirin is typically highly effective at
inhibiting COX-1 production of TXA2, this mechanisms relies on the idea of a COX-1
independent pathway leading to ongoing platelet TXA2 production. An alternate pathway
for TXA2 production could be production via the COX-2 isoform, either from circulating
platelets of the vascular endothelium.28,37 Genetic differences in the polymorphism of the
COX-1 and/or COX-2 enzymes could affect individual sensitivities to aspirin. In order to
inhibit COX-2 in people, a much higher dose of aspirin is needed than that needed to
inhibit COX-1. COX-1 will be inhibited in people at doses of much less than 325 mg of
aspirin per day (a typical human low dose of aspirin is 81 mg per day), but doses of
greater than 325 mg per day are needed to inhibit the COX-2 enzyme.28 A human low
dose of aspirin of 81 mg is comparable to the dose of aspirin that is likely sufficient to
inhibit COX-1 synthesis of TXA2 in dogs (0.5 to 1 mg/kg per day).53 Low dose aspirin
administration can lead to an increase in COX-2 expression in dogs possibly due to up
regulation of the enzyme.39 In dogs receiving anti-inflammatory or high dose aspirin (10
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mg/kg twice daily), COX-2 was found to be more consistently decreased.61 This suggests
that a 0.5-1 mg/kg per day dose might not be adequate for inhibition of COX-2 mediated
thromboxane production.
Another possible mechanism to explain aspirin resistant may be variation in
platelet thromboxane receptors. Thromboxane production in dogs receiving low-dose
aspirin has been reported to be consistently inhibited, despite the fact that platelet
function is only inhibited in one third. 39 This phenomenon suggests that there was a high
degree of variability in platelet responsiveness to thromboxane. Genetic differences in
thromboxane receptor structure might explain the different responses seen in individual.
Genetic polymorphisms in other receptors that are involved in platelet function may also
contribute to aspirin resistance. Polymorphism of PLA2, the gene coding for platelet GP
IIIa, for example, has been associated with aspirin resistance in people.72,76
The term ‘aspirin resistance’ may actually encompass multiple mechanisms and
phenomena. Three types of aspirin resistance have been identified in humans using a
combination of in vivo and in vitro techniques utilizing platelet aggregometry.
Individuals with type I aspirin resistance showed no affect on platelet aggregation or
thromboxane synthesis with oral aspirin treatment, but marked suppression of
aggregation and thromboxane synthesis with in vitro aspirin incubation. Type I aspirin
resistance therefore has the potential to be due to variability in aspirin
pharmacokinetics.77 Type II aspirin resistance is characterized by patients that had no
inhibition of platelet aggregation or thromboxane synthesis with oral aspirin therapy, and
only partial inhibition of thromboxane synthesis and no significant inhibition of
aggregation with in vitro aspirin incubation. The mechanisms behind type II aspirin
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resistance are unknown, but the phenomenon may arguably be due to increased COX-2
expression or polymorphisms in the COX-1 gene.78,79 Finally, type III aspirin resistance
is characterized by patients that show inhibition of thromboxane synthesis with both oral
aspirin and in vitro aspirin incubation, but no inhibition of platelet aggregation with either
oral treatment or the in vitro additional of aspirin. Type III aspirin resistance has also
been termed ‘pseudo-resistance’ as the aspirin appears to be exerting the expected
pharmacodynamic affect on platelets, but platelet function is not affected, allowing for
normal aggregation.80 One potential explanation for type III aspirin resistance would be
genetic polymorphisms in thromboxane receptor responsiveness to TXA2. Interestingly,
variable thromboxane receptor responsiveness to TXA2 has been documented in dogs.81
Assessment of platelet function
There are currently a variety of options available for evaluating platelet function.
Each method comes with its own set of pros and cons. and no single method provides all
the information needed to fully assess a patient’s platelet function. Determining which
test or instrument should be used can be challenging, and is based on an understanding of
the individual patient and clinical suspicion of the type of dysfunction suspected.
Ultimately, it may require the use of multiple techniques or tests to fully elucidate cause
or extent of changes in platelet function.
Multiple factors can affect which method for testing platelet function is chosen.
Some tests are better able to evaluate drug effects on platelets, while others may better
clarify hereditary or acquired function defects. Cost can have a large impact on not only
the willingness of an owner to agree to testing, but also the availability of expensive
instruments needed to run these tests. Advanced training may be needed in order to
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operate specialty instruments and, due to special handling and time constraints, certain
tests may be impractical for clinical use. There is a need for the development of patient
side tests that deliver rapid and cost-effective results. However, these more user friendly
options must first be proven to offer the same consistent and reliable results that we
expect from the established laboratory methods already in place.
Platelet Aggregometry
Platelet aggregometry has been used for over 50 years, and is considered the gold
standard for evaluation of platelet function.59,82,83 Aggregometry uses either whole blood
or platelet rich plasma in combination with an agonist that activates platelets.
Aggregometry is then used to determine the ability of platelets to aggregate and form a
platelet plug.82,83 Aggregometry evaluates platelet function under low shear stress. The
use of platelet aggregometry does have a number of drawbacks: it is time consuming,
requires the use of expensive equipment and specialized training and, since samples must
be processed shortly after collection, is difficult to utilize in a routine clinical setting.82
There are two forms of platelet aggregometry available: turbidimetric aggregometry and
impedance aggregometry.
Turbidimetric aggregometry
Turbidimetric (light transmission) aggregometry is considered more sensitive to
subtle changes in aggregation compared to impedance aggregometry, and is therefore
considered the preferred standard. Turbidimetric aggregometry utilizes sodium-citrated
platelet rich plasma (PRP) and works by measuring the amount of light that is transmitted
through the PRP after activation with a platelet agonist. A variety of agonists are
11

available for use with selection based on desired assessment and include collagen, ADP,
thrombin, arachidonic acid, epinephrine, and others. A spectrophotometer records the
light transmitted through the PRP as it is continually stirred over a set time period. The
basis of the process is that as more aggregation occurs, more light will be transmitted
through the PRP. A platelet poor plasma (PPP) sample is used from the same animal to
act as a control. The aggregometer is adjusted such that the PPP sample represents 100%
light transmission. The starting point of the curve is set to 0%. The results are displayed
dynamically as a graphed curve, and parameters measured include maximal amplitude of
aggregation (percentage) and a slope/rate (percentage/minute). The graph often shows an
initial decrease in light transmission as activated platelets undergo shape change from
discoid to spiny spheres, followed by a progressive increase in light transmission that will
plateau as permanent and irreversible aggregation occurs. With weaker agonists, it is
possible to see a biphasic aggregation with an early plateau signifying primary
aggregation, followed by a secondary wave of irreversible secondary aggregation.84,85
Turbidimetric aggregometry is useful for the evaluation of both hereditary and
acquired platelet dysfunction, as well as for monitoring of drug-induced platelet
dysfunction. However, the results can be affected by multiple factors such as agonist
type and concentration, stir speed, sample handling protocols, time elapsed from
collection, and arguably platelet count.85 Current recommendations are against adjusting
PRP in order to have a standardized platelet count before the PRP is placed in the
aggregometer, since this process appears to be unnecessary and may result in altered
platelet function due to increased sample handling. Additionally, unadjusted samples
may be a better indicator of in vivo hemostasis.86-89
12

Figure 1.1

Turbidimetric aggregometry tracing showing normal platelet aggregation in
a dog that has not received aspirin

Impedance Aggregometry
The second type of platelet aggregometry commonly used to evaluate platelet
function is impedance aggregometry. Since, unlike turbidimetric aggregometry,
impedance aggregometry does not require light transmission, whole blood can be used
instead of PRP. Impedance aggregometry employs the use of a current that passes
between two metal wires. After the addition of an agonist, platelet aggregation will begin
with the immediate adherence of platelets to the electrode wires. As the platelet plug
13

develops, the flow of current across the wires will be impaired and conduction will
diminish. Impedance aggregometry graphs aggregation in a manner similar to
turbidimetric aggregometry. Results are measured as maximal amplitude of aggregation,
but the unit of measurement is expressed in ohms.85

Figure 1.2

Impedance aggregometry tracing showing normal platelet aggregation in a
dog that has not received aspirin

Advantages of impedance aggregometry compared to turbidimetric aggregometry
include simplification of sample handling as centrifugation to create PRP is not required,
less risk of platelet function disturbance due to the extra handling needed to create PRP, a
14

shortened preparation time, need for smaller sample volumes, and effectiveness with
lipemic blood. As with turbidimetric aggregometry, various agonists are available for
use, and impedance aggregometry can also be used to evaluate acquired and congenital
platelet disorders as well as drug-induced platelet dysfunction.85
One specific impedance-type analyzer that has recently become available for use
is the Multiplate® platelet function analyzer. The Multiplate® analyzer uses impedance
aggregometry to evaluate platelet function under low, non-laminar shear conditions. The
Multiplate® analyzer works in the same manner as other impedance analyzers in that it
uses whole blood and measures conduction across an electrode. The analyzer utilizes
five channels and disposable test cells, and is a rapid and user friendly instrument option
because a computer both guides the user and controls volumes and order of procedures.
These features potentially make the Multiplate® analyzer an attractive option for clinical
use. Each test channel produces two aggregation curves and can be used separately, thus
allowing for simultaneous evaluation of platelet function under the influence of different
agonists.
The Multiplate® analyzer generates an aggregation curve and produces results
such as area under the curve, maximal aggregation, and rate of reaction. Area under the
curve is considered the best measurement of platelet function and overall aggregation
response as it is dependent on both the height and slope of aggregation.90 The
manufacturer recommends the use of non-calcium chelating anticoagulants such as
heparin or hirudin instead of the citrate used by traditional aggregometry instruments.
Thrombin inhibitors such as heparin allow maintenance of physiologic concentrations of
calcium to better represent in vivo hemostasis. However, as the samples are diluted with
15

0.9% sodium chloride during analysis, calcium levels are still likely affected to some
degree.83
Recent studies using the Multiplate® analyzer in dogs have sought to validate its
use and to determine the most appropriate combinations of anticoagulant, agonist, and
test duration. Study results to date have not as yet provided reliable recommendations for
use in dogs. While some results support its use in dogs, there remains disagreement on
the best anticoagulant option. Hirudin was recommended in one study,83 while another
study recommended that shorter run times and the use of heparin anticoagulant were
needed to optimize results91 The agonists ADP, arachidonic acid, and collagen are
effective at consistently inducing platelet aggregation with the Multiplate® analyzer, but
ristocetin and thrombin receptor activating peptide (TRAP) are not.83
PFA-100
The Siemens Platelet Function Analyzer-100® (PFA-100®) is a bench top
instrument used to evaluate platelet function. The PFA-100® has been previously
evaluated for use as a commercial point-of-care platelet function analyzer in dogs.58,59,92
The PFA-100® provides an in vitro evaluation of the time needed for formation of a
platelet plug under high shear conditions. A variety of platelet agonists can be used,
including as epinephrine, ADP and collagen.
The instrument contains an aperture that simulates the presence of damaged
vascular endothelium. Results are recorded as ‘closure time’, or the time needed for a
platelet plug to fully occlude the aperture. Use of this instrument requires sodiumcitrated whole blood, and utilizes two different types of disposable cartridges. The
collagen/epinephrine cartridge is best for evaluating drug-induced platelet dysfunction,
16

and the collagen/ADP cartridge is best for evaluating congenital or acquires platelet
function defects.93
A prolongation of the PFA-100® closure time, when measured with the
collagen/epinephrine cartridge, has been established as a sensitive indicator of aspirininduced platelet function in both humans and dogs.59 Both the collagen/ADP and
collage/epinephrine cartridges have been used as an effective test for diagnosis of von
Willebrand’s disease in dogs.94 The PFA-100® is insensitive at detecting the inhibitory
effects of ADP antagonists. 95 Although the PFA-100® could potentially be used to detect
increased platelet function, it is unclear if a shortened closure time is truly representative
of platelet hyperactivity and thromboembolic risk.
The PFA-100® measures up to a maximum closure time of only 300 seconds.
Closure times beyond 300 seconds strongly suggest platelet dysfunction. Interpretation
of closure times can be difficult, however, especially when results are in the upper ranges
of normal, and marginal values require repeated testing in order to verify results. Other
factors such as even mild thrombocytopenia (150,000/μl), decreased hematocrit, sodium
citrate anticoagulant concentration92, dog breed59, and the presence of underlying cardiac
disease96 can affect results.
Urine thromboxane
Measurement of thromboxane synthesis provides is a reliable indicator of COX
function. After thromboxane A2 undergoes metabolism, it is excreted into urine as stable
metabolites. The most abundant urine metabolite, 11-dehydro-thromboxane B2, as well
as the metabolite 2,3-dinor thromboxane B2, have been found in increased concentrations
in people in association with hypercoagulable conditions.97,98 In dogs, urinary
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concentrations of 11-dehydro-thromboxane B2 have been found to be elevated with
gastric dilatation-volvulus.97 Previous studies in humans have used urinary
concentrations of 11-dehydro-thromboxane B2 to assess aspirin-induced COX
inhibition.23,98
Urine concentrations of thromboxane metabolites are preferred to plasma or
serum levels as the mere act of blood collection and processing can lead to platelet
activation and thromboxane synthesis. Platelet activation during blood sample collection,
storage, and processing can lead to artifactually increased thromboxane concentrations
that not indicative of true in vivo activity. For this reason, urine thromboxane metabolite
levels are considered a more reliable measure of TXA2 synthesis.23,24 The urinary
concentration of the metabolites 11-dehydro-thromboxane B2 and/or 2,3-dinor
thromboxane B2 are preferred indicators of platelet thromboxane production compared to
urinary thromboxane B2, because thromboxane B2 can be generated by the kidneys and
excreted without undergoing metabolism.97
It has not yet been shown which of the two urinary metabolites, 11-dehydrothromboxane B2 or 2,3-dinor thromboxane B2, best indicates in vivo platelet response to
aspirin in dogs.22 Disadvantages of using 11-dehydro-thromboxane B2 include its low
concentration in urine thus requiring minimal dilution during measurement that could
allow for more interference as well as concerns about the metabolites relevance in
indicating TXA2 release from platelets. 22,99,100 However, the metabolite is used
commonly in human medicine allowing extensive opportunity for comparison and thus
extrapolation, even though possible differences between the affects of aspirin on venous
versus arterial thrombosis remains unclear.22
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The measurement of 2,3-dinor thromboxane B2 offers the advantages of high
urine concentrations in dogs making it easily detectible however it it has the potential to
cross react with TXB2 concentrations when measured using the ELISA method. This
may be more of a concern in dogs with renal disease producing altered concentrations of
renal TXB2.22 2,3-dinor thromboxane B2 has a shorter half life than 11-dehydrothromboxane B2 which has the potential to create more fluctuation in urine levels.
Assays for this metabolite are less readily available and as it is not frequently measured
in human medicine, there is little literature available for comparison or extrapolation.22
Additional methods for evaluating platelet function
Several other methods exist for evaluating platelet function. The buccal mucosal
bleeding time (BMBT) is the most frequently used method in dogs for assessing platelet
function in vivo. This test involves creating a small incision on the inside of the lip and
measuring the time it takes for bleeding to be halted by the formation of a platelet plug.
This same concept can also be assessed using a toe nail clip, however, the nail cuts may
be less consistent and lead to more variable results. Both methods are affected by
thrombocytopenia and are insensitive measures of drug induced platelet dysfunction.
The VerifyNow® platelet function analyzer is a point of care instrument that uses
a technique similar to light aggregometry but in the form of disposable cartridges already
preloaded with a platelet agonist. The different cartridges available were designed to
evaluate the anti-platelet effects of drugs such as aspirin (arachidonic acid), P2Y12
inhibitors (ADP and prostaglandin E1), and GP IIb/IIIa antagonists (iso-thrombin
receptor-activating peptide). This instrument was designed for use in people, and has
limits when applied to canine use, especially when evaluating the effects of aspirin.95
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Canine platelets show variable response to arachidonic acid as well as iso-thrombin
receptor-activating peptide (iso-TRAP) thus making this instrument an unreliable
measure of the affects of aspirin or GPIIb/IIIa antagonists on canine platelet function.101
As this method has so far seen limited use in the veterinary field, further research is
needed using the VerifyNow® in veterinary patients to truly understand its capabilities
and limitations.
The PlateletWorks® platelet function kit acts to indirectly evaluate platelet
function by using a standard impedance cell counter to measure platelet counts before
and after activation by several different agonists. Results are then reported as percent
aggregation and percent inhibition. While this is a simple point-of-care test that offers
rapid results, it is not only extremely time dependent but also strongly affected by
individual user and, so far ,appears to lack correlation with other available tests of platelet
function. Limited research with canine platelets is available for the PlateletWorks®
platelet function kit.
Tests to evaluate platelet adhesion are also available. The DiaMed Impact-R®
tests platelet function under close to physiological flow conditions by using imaging
technology to measure platelets adhered and aggregated to well surface. However,
limited research is available to assess use of the Impact-R® in veterinary patients. Various
immunoassays, particularly enzyme-linked immunosorbent assays (ELISAs), and
collagen binding assays have also been developed to measure the quantity and function of
canine von Willebrand’s factor, which plays a critical role in platelet adhesion.
Platelet role in clot stability can also be assessed using thromboelastography
(TEG) or viscoelastometry, however this technology remains available in only limited
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settings at this time, and its utility for evaluating this aspect of platelet function in dogs
has not been established.
Primary hemostasis can also be assessed using a clot retraction test. This is a
crude measure of clot formation that works by measuring the time it takes for a blood clot
to form and then retract away from the walls of a glass container. Retraction normally
takes 1-2 hours and is dependent upon a normal platelet count and normal platelet
function.
Finally, flow cytometry can be used to evaluate platelet surface protein expression
both before and after activation, and has a wide variety of applications to look at
hereditary, acquired, immune, and drug induced platelet dysfunction. Unfortunately,
limited availability, and the need for rapid sample handling and specialized
instrumentation and expertise, create challenges for the routine clinical application of
flow cytometry.
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CHAPTER II
EFFECTS OF LOW DOSE ASPIRIN ON PLATELETS

Introduction
Thromboembolism is an important complication of many conditions affecting
dogs, including immune-mediated hemolytic anemia, hyperadrenocorticism, and protein
losing nephropathy.1,2 Low-dose aspirin is often recommended for the prevention of
thromboembolic complications in humans and dogs. Unfortunately, despite low-dose
aspirin therapy, a subset of patients still develop thromboembolic complications, a
phenomenon known in human medicine as ‘aspirin resistance’. The exact incidence of
aspirin resistance in humans is unknown, but the phenomenon is estimated to affect up to
45% of human patients.3-6
Aspirin is a cyclooxygenase (COX) inhibitor that irreversibly inhibits platelet
function. By inhibiting COX, aspirin blocks the arachidonic acid conversion pathway and
prevents the synthesis of prostaglandins, particularly thromboxane A2 (TXA2) and
prostacyclin (prostaglandin I2), which work in concert to maintain a balanced, normal
hemostatic system.5 In contrast to TXA2, which is produced by platelets to enhance
local vasoconstriction, activate platelet adhesion, and promote platelet aggregation,
prostacyclin originates from the vascular endothelium and has the opposite physiologic
effect on primary hemostasis (vasodilation and inhibition of platelet aggregation).7 After
synthesis, TXA2 has an immediate physiologic effect, and is then metabolized to
31

thromboxane B2 and further metabolized into 11-dehydro-thromboxane B2 (11-dTXB2)
and 2,3-dinor-thromboxane B2 (2,3-dinorTXB2) before being eliminated in the urine.8-10
Measurement of urinary 11-dTXB2 has been used as an indicator of aspirin-induced COX
inhibition.9,11-13
Anti-inflammatory doses of aspirin (10 mg/kg orally twice daily) reliably inhibit
platelet function in dogs by decreasing TXA2 production, but can cause gastrointestinal
and renal side effects.11 Lower dosages (0.5-1 mg/kg orally once daily) of aspirin are
used to maintain anti-platelet effects without significant adverse effects.14 Low doses of
aspirin, however, do not consistently inhibit platelet function in all dogs. Dudley et al.
documented that low-dose aspirin therapy only completely and consistently inhibits
platelet function in about one third of dogs, as measured by prolongation in closure times
using a point-of-care platelet function analyzer (PFA), while remaining dogs either do not
respond or inconsistently respond.15 There is currently no pre-treatment diagnostic test
that can reliably predict which dogs will respond to the anti-platelet effects of low-dose
aspirin therapy.
In both human and veterinary medicine, platelet aggregometry is considered the
gold standard method for evaluation of platelet function.16-18 Platelet aggregometry
analyzes platelet function by using specific agonists to activate platelets in either platelet
rich plasma (PRP) (turbidimetric aggregometry) or whole blood (impedance
aggregometry), and measuring the ability of platelets to aggregate.17 Unfortunately,
platelet aggregometry is expensive, labor intensive, and requires specialized equipment
and training, thus making aggregometry difficult to utilize in a clinical setting.11 Pointof-care PFAs have the potential to generate similar information to platelet aggregometers
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about platelet function, and are more user-friendly instruments in a clinical setting.
Correlating the results between platelet aggregometry and point-of-care PFAs, especially
during low-dose aspirin therapy, may enable the establishment of point-of-care PFAs as
user friendly instruments for identifying aspirin resistance in canine clinical patients
during initial treatment.
In humans, a pre-treatment protocol has been developed for determining an
individual patient’s response to the anti-platelet effects of aspirin, as well as
characterizing the nature of aspirin resistance when it is detected. This protocol involves
in vitro exposure of platelets to acetylsalicylic acid followed by platelet aggregometry.19
We hypothesized that this same in vitro protocol, performed on platelet samples collected
prior to aspirin therapy, may similarly allow prediction of response or non-response to
low-dose aspirin in dogs.
The objectives of our study were to develop and evaluate a protocol utilizing
turbidimetric platelet aggregometry and in vitro platelet incubation in acetylsalicylic acid
to determine the degree of aspirin-induced platelet inhibition in dogs, and to determine if
this technique could reliably and accurately predict the degree of in vivo aspirin-induced
platelet dysfunction. Additionally, in dogs receiving low-dose aspirin, an attempt was
made correlate the results of turbidimetric aggregometry with point-of-care PFA results.
Materials and methods
Study Population:
Healthy client-owned adult dogs were recruited from students, staff, clients, and
faculty associated with the Mississippi State University College of Veterinary Medicine.
Informed owner consent was obtained before initiation of the study. The dogs did not
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receive any medications or vaccines for at least two weeks prior to the initiation of the
study, and no medications, other than aspirin, were administered during the testing
period. Aspirin dosing was based on body weight obtained at the beginning of the study.
Weight was rounded to the nearest whole kilogram. Normal health status was established
via physical examination, complete blood count, serum chemistry, urinalysis, heartworm
testing and platelet function analysis using a point-of-care platelet function analyzer(a)
(collagen/ADP cartridge(b)). Dogs were excluded from the study if they were found to
have abnormalities on physical examination, urinalysis, complete blood count or serum
chemistry that could impact platelet function, heartworm or tick-borne disease, or platelet
abnormalities based on either an abnormal platelet count or prolonged PFA closure time.
Animal use was approved by the Mississippi State University Institutional Animal Care
and Use Committee.
Study Design
Aspirin(c) was administered orally to each dog at a dose of 1 mg/kg once daily in
the morning for 7 days. Based on initial bodyweight, aspirin doses were compounded
into capsules by the Mississippi State University College of Veterinary Medicine
Pharmacy. Blood and urine samples were collected from all study participants for
platelet function evaluation using platelet aggregometry and PFA(a) (collagen/epinephrine
cartridge(d)) and urinary 11-dTXB2 analysis on Day 0 (prior to initiating aspirin), and
again on Days 3 and 7 during aspirin administration. Blood samples were collected via
jugular venipuncture with a 20 gauge needle directly into a 4.5 ml vacutainer tube
containing 3.2% sodium citrate(e) or hirudin (f) anticoagulant. Each sample was collected
until the tube was completely filled to standardize the degree of anticoagulation. For
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urine samples, an initial attempt was made to collect urine via free catch but, if
unsuccessful, cystocentesis using a 22-gauge 1.5 inch needle with a 12 ml syringe was
performed. The volume of urine collected varied between 3 and 10 mls. Blood and urine
samples were collected between 2 and 5 hours, and 2 and 8 hours, after drug
administration, respectively.
Platelet Aggregometry
Platelet aggregometry was performed using three different methods: turbidimetric
and impedance aggregometry using a conventional aggregometer, and impedance
aggregometry using a more recently developed multiple electrode aggregometer.
Conventional Aggregometer
A combined turbidimetric and impedance two channel platelet aggregometer(g)
that allowed for two samples to be evaluated concurrently was used to analyze platelet
aggregation in both platelet-rich plasma (turbidimetric) and whole blood (impedance).
For each dog and time point, four total samples were analyzed, and the results were
averaged to yield a single value at each time point. Aggregation was assessed using
collagen as an agonist (final concentration 10 μg/mL4-6), a temperature of 37oC, and a
stirring speed of 1,200 rpm. All samples were analyzed within four hours of collection.
When compared to baseline (Day 0), a dog was considered to be an aspirin-responder if
there was a greater than 25% reduction in maximal aggregation compared to pretreatment values.20
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Turbidimetric Aggregometry
To harvest platelet-rich plasma (PRP), whole blood collected into 3.2% sodium
citrate was centrifuged at 1,200 rpm at room temperature for 3 minutes. Supernatant PRP
was collected, and the remaining blood sample was centrifuged at 1,800 rpm at room
temperature for 8 minutes to create platelet-poor plasma (PPP).
Samples were analyzed based on the manufacturer’s standard guidelines(h).
Briefly, 450 µl of PRP was transferred into a glass cuvette containing a siliconized
magnetic stir bar, and 500 µl of PPP was placed into a cuvette without a stir bar.
Samples were incubated, at 37oC, for 5 minutes, and placed into the aggregometer, and
stable baseline values for minimal (PRP) and maximal (PPP) aggregation were obtained
(0% and 100%, respectively). Collagen was then added to the PRP sample, and
aggregation was monitored for 12 minutes. The maximal percentage aggregation was
calculated and recorded by using a program provided with the aggregometer(i).
Impedance Aggregometry
Samples were analyzed based on previously described protocols and the
manufacturer’s standard guidelines(h). Briefly, 450 µl of saline and then 450 µl of
citrated whole blood were transferred to a plastic cuvette containing a magnetic stir bar.
Following incubation at 37oC for 5 minutes, samples were placed into the aggregometer,
an impedance probe was inserted into each cuvette, and a stable baseline was obtained.
Collagen was then added to the sample and aggregation was monitored for 12 minutes.
The maximal amplitude, measured in ohms, was calculated and recorded as an indicator
of maximal aggregation.

36

Multiple Electrode Aggregometer
Additional impedance analysis was performed using a recently available multiple
electrode aggregometer(j), and analysis was based on the manufacturer’s
recommendations(k). Aggregation was assessed using a collagen concentration of 10
μg/mL4-6, a temperature of 37oC, and a stirring speed of 1,200 rpm. 3 mls of blood was
collected directly into a hirudin anticoagulant tube and transferred into a single-use test
cell containing a dual sensor unit, a Teflon-coated magnetic stir bar, and warmed saline.
Volumes for analysis were controlled by the automated pipette provided with the
instrument. Within the dual sensor unit, the electrical resistance between the sensor wires
was recorded. The change in impedance caused by platelet adhesion and aggregation on
the electrodes was continuously detected. Collagen was added to the sample and
aggregation was monitored for 12 minutes. Platelet aggregation was analyzed and
recorded as area under the curve (AUC). For each dog and time point, four total samples
were analyzed, and the results were averaged to yield a single value at each time point.
All samples were analyzed within four hours of collection. When compared to baseline
(Day 0), a dog was considered to be an aspirin-responder if there a greater than 25%
reduction in maximal aggregation compared to pre-treatment values.20
Platelet Function Analysis
A commercial point-of-care platelet function analyzer(a) that has previously been
evaluated for use in dogs16,21-23 was used to analyze platelet function. This PFA is an in
vitro platelet function analyzer that mimics a high shear force over an area of vascular
damage, and stimulates platelet function with several platelet agonists to measure the
closure time, in seconds, needed to form a platelet plug and inhibit blood flow. The cut37

off time for the instrument is >300 seconds. All cartridges were stored at 4C and
warmed to room temperature prior to analysis.
Samples were collected directly into 4.5 ml blood collection tubes containing
3.2% sodium citrate, gently mixed, and kept at room temperature without agitation until
analysis. The instrument was used according to manufacturer’s instructions. For
analysis, 800 l of whole blood was transferred into either a collagen/ADP cartridge
(performed initially to establish normal platelet function) or collagen/epinephrine
cartridge (used throughout the study to assess aspirin-associated platelet dysfunction).
Two collagen/epinephrine cartridges were analyzed at each time point for all dogs, and
the closure times were averaged. All samples were analyzed within four hours of
collection.
A dog was considered to be an aspirin-responder if the closure time on Day 7 was
>300 seconds (ie. both cartridges were >300 seconds).24 If, on Day 7, a dog had one
cartridge <300 seconds and one cartridge >300 seconds, a third, ‘tie-breaker’ sample was
analyzed.
In Vitro Aspirin Incubation
Following at least a two week washout period where no medications were
administered, an additional 12 mls of blood was collected from each dog into 3.2%
sodium citrate anticoagulant.25 Acetylsalicylic acid was prepared via dissolution in 100%
ethanol to create a 400 μM solution. In vitro incubation of platelets with acetylsalicylic
acid was then performed, based on a previously described protocol.19 Briefly, 100 μM of
acetylsalicylic acid was added to 1 ml of PRP prepared by the previously described
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technique, and incubated at room temperature for 15 minutes. Following this incubation,
platelet aggregation was assessed via turbidimetric aggregometry, using the same
technique that was previously described. All samples were analyzed in quadruplet and
maximal percentage amplitude was averaged. To ensure that 100% ethanol alone would
not influence platelet aggregation, PRP was also incubated for 15 minutes at room
temperature with an equal volume of 100% ethanol for each dog. A dog was considered
to be an aspirin-responder if there was greater than 25% reduction from Day 0 (baseline)
results in the maximal percentage aggregation.20
Urine 11-dehydro-thromboxane B2 Analysis
Urinary 11-dehydro-thromboxane B2 (11-dTXB2) concentration was analyzed
using a commercially available enzyme-linked immunosorbent assay kit(i) that has been
previously validated in the dog.26 Urine samples was collected via free catch or
cystocentesis and stored at -80°C for later analysis. Prior to analysis samples were
thawed to room temperature and the assay buffer was used to dilute each sample. A
correction factor was applied to account for these dilutions. Samples were analyzed in
triplicate according to the manufacturer’s instructions(i), and reported in picograms per
milliliter of urine. Briefly, a 96-well plate was prepared by adding 50 µl of each dilute
sample (vortexed thoroughly), 50 µl of 11-dTXB2 monoclonal AChE tracer and 50 µl of
11-dTXB2 monoclonal antibody to each well. Each plate was incubated at room
temperature, in the dark and on an orbital shaker, for two hours, followed by the addition
of Ellman’s Reagent. Following a one hour incubation at room temperature, in the dark
on an orbital shaker, each plate was analyzed a wavelength of 412 nm using a plate
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reader(j) . Urine creatinine concentration was measured using a biochemistry analyzer(k)
and used to calculate a urinary 11-TXB2-to-creatinine ratio.27,28
Statistical Methods:
The means of the replications of measurement for each sample by each instrument
were used in the statistical analyses. Histograms were used to visually assess if the
turbidimetric, impedance, multiple electrode impedance, PFA and in vitro aspirin
incubation aggregometry measurements were normally distributed using PROC
UNIVARIATE in SAS for Windows 9.3(l). The variables were found to not be normally
distributed. Accordingly, a nonparametric analysis, Spearman Rank Correlation, using
PROC CORR in SAS for Windows 9.3 was used to assess the correlation among the
variables. A p value <0.05 was considered significant for all analyses.
Dogs were categorized as aspirin-responders or non-responders according to the
results of each instrument for the Day 3 and Day 7 measurements. Agreement between
the turbidimetric aggregometry response and each of the other instruments as well as
between impedance and PFA results was assessed for Day 3 and Day 7 using PROC
FREQ in SAS for Windows 9.3. Due to the sparse data in some cells, exact methods
were used to determine the Kappa statistic. A scale proposed by Landis and Koch29
(1977) was used to classify the strength of agreement. According to these guidelines,
Kappa less than 0 equals “poor” agreement, 0.00 – 0.20 as “slight”, 0.21 – 0.40 as “fair”,
0.41-0.60 as “moderate”, 0.61-0.80 as “substantial” and 0.81-1.00 as “almost perfect”.
An alpha level of 0.05 was used to determine statistical significance for all methods.
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Results
Study Group Characteristics
A total of 36 dogs were initially screened for inclusion in the study, but 18 dogs
were excluded due to problems with availability during the study period, positive results
on infectious disease screening, pre-treatment thrombocytopenia, persistent lipemia, and
the need for unexpected and unrelated surgery during the study period. Two further dogs
were excluded from the study because an initial baseline PFA collagen/epinephrine
cartridge closure time was greater than 300 seconds. A total of 16 dogs met the inclusion
criteria and participated in the study. Mixed breed dogs were most common (n=4). There
were 9 different breeds of purebred dogs, including Australian Shepherds (n = 2),
Labrador Retrievers (n=2), Pit bull terriers (n=2), and one of each of the following:
Alapaha Bulldog, German Shorthaired Pointer, Great Dane, Greyhound, Pembroke
Welsh Corgi, and Standard Poodle. The study population consisted of 6 neutered males,
2 intact males, 7 spayed females, and 1 intact female. The mean age was 4.75 years
(range, 1-9 years old) and the mean body weight was 29.07 kg (range, 14.2-50.5 kg). The
16 dogs received aspirin for 7 days with no reported adverse effects.
Conventional Turbidimetric Aggregometry
The mean turbidimetric aggregometry amplitude for all 16 dogs on Day 0 was
54.4% (range, 28.8-71.5%), while the mean amplitude for all dogs on Day 3 and Day 7
was 28.2% (range, 0.8-62.8%) and 20.6% (range, 0.8-55.8%), respectively. When
compared to Day 0, there was a significant decrease in amplitude at both Day 3 (p<0.001)
and Day 7 (p<0.001). There was no significant difference in amplitude between Days 3
and 7 (p=0.414). Mean turbidimetric amplitude was decreased by >25% (aspirin41

responsiveness) in 13 dogs (81.3%) at Day 3 and in 13 dogs (81.3%) at Day 7. Only two
dogs were considered to be non-responders on both days. Two dogs inconsistently
responded to low-dose aspirin between Day 3 and 7: one dog was classified as a
responder on Day 3 and a non-responder on Day 7, and a second dog was classified as a
non-responder on Day 3 and a responder on Day 7.
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Figure 2.1

Amplitude (percentage) of aggregation of turbidimetric aggregometry

Turbidimetric aggregometry in 16 healthy dogs during treatment with low-dose aspirin (1
mg/kg PO every 24 hours for 7 days). There was a significant decrease in amplitude
from Day 0 to Day 3 (P<0.001) (*) and from Day 0 to Day 7 (P<0.001) (**). There was
no significant difference between Day 3 and Day 7. In vitro incubation with aspirin is
shown for comparison. The box and whiskers plot demonstrates the median (line),
interquartile range (box), and total range (whiskers).
Conventional Impedance Aggregometry
The mean impedance aggregometry amplitude for all dogs on Day 0 was 5.5 ohm
(range, 0.8-13.8), while the mean amplitudes for all dogs on Day 3 and Day 7 were 2.4
ohm (range, 0-13.8 ohm) and 1.8 ohm (0-13 ohm), respectively. Due to unexpected
machine error or insufficient sample volume, samples were only analyzed in triplicate
(rather than quadruplicate) in five different dogs: 2 dogs on Day 0, 2 dogs on Day 3, and
one dog on Day 7. When this occurred, the 3 results were averaged and incorporated into
the analysis.

When compared to Day 0, there was a significant decrease in amplitude at

both Day 3 (p<0.001) and Day 7 (p<0.001). There was no significant difference in
amplitude between Days 3 and 7 (p=1.00). Mean impedance amplitude was decreased by
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>25% (aspirin-responsiveness) in 13 dogs (81.3%) at Day 3 and in 13 dogs (81.3%) at
Day 7. One dog was considered to be a non-responder on both days. Four dogs
inconsistently responded to low-dose aspirin between Day 3 and 7: two dogs were
classified as responders on Day 3 and non-responders on Day 7, and two dogs were
classified as non-responders on Day 3 and responders on Day 7.
When compared to aspirin responsiveness as determined by turbidimetric
aggregometry, impedance aggregometry identified all of the same aspirin responders and
non-responders on Day 3. However impedance only found 10 of the 16 dogs to have the
same classification of aspirin response as turbidimetric on Day 7 (all were classified as
aspirin responders). Impedance aggregometry results did not identify as non-responders
any of the 3 dogs that were classified as aspirin non-responders via turbidimetric
aggregometry on Day 7.
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Figure 2.2

Amplitude of aggregation of impedance aggregometry in ohms

Impedance aggregometry in16 healthy dogs during treatment with low-dose aspirin (1
mg/kg PO every 24 hours for 7 days). There was a significant decrease in amplitude from
Day 0 to Day 3 (P<0.001) (*) and from Day 0 to Day 7 (P<0.001) (**). There was no
significant difference between Day 3 and Day 7 (P=1.0). The box and whiskers plot
demonstrates the median (line), interquartile range (box), and total range (whiskers).
Multiple Electrode Aggregometer
Multiple electrode aggregometry results were only available for 9/16 dogs due to
loss of instrument availability. Mean AUC for all 9 dogs on Day 0 was 1,681.7 U (range,
1,042.5-2,304.3 U). Mean AUC for Days 3 and 7 was 1,762.1 U (range, 1,280-2,944.8
U) and 1,960.9 U (range, 1,107.3-2,514.5 U) respectively. There were no significant
differences in the AUC between Days 0 and 3, Days 0 and 7, and Days 3 and 7. Eight of
the 9 dogs on Day 3 and all of the dogs on Day 7 were classified as aspirin nonresponders.
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When compared to aspirin responsiveness as determined by turbidimetric
aggregometry, the multiple electrode aggregometer did not identify any of the same
responders or non-responders on Day 3. In fact, the only aspirin responder identified via
the multiple electrode aggregometer on Day 3 was classified as a non-responder with
turbidimetric aggregometry. On Day 7, only one dog had the same classification (nonresponder) with the multiple electrode aggregometer as with turbidimetric aggregometry.
Platelet Function Analysis
The mean point-of-care PFA collagen/epinephrine closure time for all 16 dogs on
Day 0 was 119.7 seconds (range, 90-163 seconds), while the mean closure time of all
dogs on Days 3 and 7 was 214 seconds (range, 112-300 seconds) and 232.7 seconds
(range, 157.5-300 seconds), respectively. When compared to Day 0, there was a
significant increase in closure times at both Day 3 (p < 0.001) and Day 7 (p < 0.001).
There was no significant difference in closure times between Days 3 and 7 (P=0.634).
The mean PFA closure time was greater than 300 seconds (aspirin-responsiveness) in 4
dogs (25%) on Day 3 and 7 dogs (43.8%) on Day 7. However, only 3 dogs were
consistently greater than 300 seconds on both days. On Day 7, 5 dogs (31.3%) required a
third sample to assist in the classification of aspirin responders or non-responders.
When compared to aspirin responsiveness as determined by turbidimetric
aggregometry, PFA results only identified 4 of the same aspirin responders and 3 of the
same non-responders on Day 3, and identified 5 of the same responders and only one
non-responder on Day 7. PFA results identified the same categorization as turbidimetric
aggregometry (responder versus non-responder) at Day 7 in 6/16 dogs. The PFA only
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identified one of 3 dogs that were classified as non-responders by turbidimetric
aggregometry on Day 7.

Figure 2.3

PFA closure times

PFA-100 closure times in 16 healthy dogs during treatment with low-dose aspirin (1
mg/kg PO every 24 hours for 7 days). There was a significant increase in closure time
from Day 0 to Day 3 (P<0.001) (*) and from Day 0 to Day 7 (P<0.001) (**). There was
no significant difference between Day 3 and Day 7 (P=0.634). The box and whiskers
plot demonstrates the median (line), interquartile range (box), and total range (whiskers).
In Vitro Turbidimetric Aggregometry
The mean turbidimetric amplitude for all dogs following in vitro incubation with
salicylic acid was 4% (range, 1-10%). The mean percent reduction from baseline for
amplitude was 91.9% (range, 66.7-98%). All of the dogs demonstrated marked
suppression in amplitude after in vitro incubation with salicylic acid, however, some
residual platelet function did persist in three dogs as evidenced by weak aggregation.
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Nevertheless, the reduction in amplitude from baseline was greater than 25% in all dogs,
which categorized them all as aspirin-responders.

Figure 2.4

Prevalence of aspirin non-responders

Identified based on platelet function testing performed.
Urine 11-dehydro-thromboxane B2 Assay
The mean urine 11-dTXB2-to-creatinine ratio on Day 0 was 4.8 (range, 2.0-9.1),
while the median ratios for Day 3 and Day 7 were 3.5 (range, 0.8-8.1) and 3.3 (range,
0.8-13.5), respectively. There was a 34.7% decrease in the urine 11-dTXB2-to-creatinine
ratio between Day 0 and 3, a 49% decrease between Day 0 and 7, and 21.9% decrease
between Day 3 and 10. There was no significant change in the urinary 11-dTXB2-tocreatinine ratio between Day 0 to 3 (p=0.315) and Day 3 and 7 (p=0.664). However,
there was a significant decrease from Day 0 to 7 (p=0.028). Urine 11-dTXB2 results
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from 3 dogs on Day 0 and 2 dogs on Day 7 were unavailable because the concentrations
were below the detection level of the assay.
Correlation
When the data from all three sample days were combined, the results from
turbidimetric aggregometry were significantly correlated with impedance (r=0.63,
p<0.001) and PFA (r=-0.56, p<0.001). In addition, impedance aggregometry was
significantly correlated with PFA results (r=-0.55, p<0.001). When the data for each day
were analyzed separately, no significant correlations were detected on Day 0 (p>0.099) or
Day 7 (p>0.197). On Day 3, turbidimetric aggregometry was significantly correlated
with impedance aggregometry (r=0.66, p=0.0052). Impedance aggregometry was
correlated with PFA results (r=-0.49) with a p value approaching the level of significance
(p=0.0532).
Agreement
The Kappa statistic was used as a measure of agreement for classification as
aspirin-responder or non-responder between turbidimetric aggregometry and the other
tests of platelet function, and between impedance aggregometry and PFA results.
Agreement between aspirin responders or non-responders was determined for both Day 3
and Day 7. The only significant agreement occurred on Day 3 with perfect agreement
(Kappa=1.00, p=0.002) between turbidimetric and impedance aggregometry.
Discussion
When discussing the concept of aspirin resistance it is important to differentiate
between “clinical” aspirin resistance and “laboratory” aspirin resistance. Clinical aspirin
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resistance occurs when low dose aspirin does not protect individuals from a
thromboembolic event. Laboratory aspirin resistance is when aspirin does not show an
antiplatelet effect when assessed with in vitro tests of platelet function. Ideally, these two
concepts would be correlated allowing for the prediction of clinical aspirin resistance
through the identification of laboratory aspirin resistance. In our study, we attempted to
better evaluate multiple laboratory methods in order to work toward better prediction and
therefore improved clinical handling of patients with possible aspirin resistance.
Turbidimetric aggregometry is considered to be the gold standard method for
assessing drug-induced platelet dysfunction in humans receiving aspirin. In dogs
receiving aspirin, turbidimetric aggregometry was the most consistent of all of the tests of
platelet function used in our study at identifying aspirin-responders or non-responders on
both Days 3 and 7. With turbidimetric aggregometry, there were only two dogs that were
inconsistently identified as either a responder or non-responder between Day 3 and Day
7. Impedance aggregometry was the second most consistent methodology at identifying
aspirin responders or non-responders, with 4 dogs being inconsistently classified between
Day 3 and Day 7, and the point-of-care PFA was the third most consistent instrument
with 5 inconsistent classifications between Day 3 and Day 7. Our results are comparable
to those of a previous study that evaluated the anti-platelet effects of low-dose aspirin in
dogs 15, which also demonstrated inconsistencies in the aspirin-response classification of
individual dogs on different days. Since, the anti-platelet effects of aspirin are typically
expected to occur within minutes of ingestion of acetylsalicylate in people,30 the platelet
function results on Day 3 and Day 7 would be expected to be comparable, suggesting that
the tests used in our study do not reliably detect aspirin-responsiveness in individual dogs
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on a day-by-day basis. However, alternatively, the discrepancy between Day 3 and Day
7 results may not reflect inconsistent aspirin-responsiveness, but rather may reflect
delayed drug effects that may not be fully evident until Day 7. In some dogs, the response
to aspirin appears to change over time. One dog, based on turbidimetric results, and 2
dogs, based on impedance results, were classified as non-responders on Day 3 but as
aspirin-responders on Day 7. These findings may suggest a progressive inhibition in
platelet function during aspirin administration. However, in contrast, one dog, based on
turbidimetric results, and 2 dogs, based on impedance results, were classified as aspirinresponders on Day 3 but as non-responders on Day 7. Possible explanations for
variability in results include decreased drug bioavailability, poor owner compliance with
drug administration, increased platelet turnover to release non-aspirinated platelets, or
expression of a variant COX-I enzyme which is less sensitive to aspirin inhibition.
Since turbidimetric aggregometry is the historical gold standard for assessment of
platelet function in patients receiving aspirin, in our study we chose to compare the
results of all other diagnostic tests with this methodology. When comparing the response
classifications between turbidimetric and impedance aggregometry, there was perfect
agreement on Day 3, with 19% of dogs being classified as aspirin non-responders.
However, on Day 7, there was not complete agreement between turbidimetric and
impedance aggregometry. Although both techniques identified 3 dogs (19%) as aspirin
non-responders, each technique identified a different 3 dogs as non-responders. In a
comparable study performed in humans that were receiving low-dose aspirin, 6 different
tests of platelet function were utilized to assess the anti-platelet effects of aspirin and the
prevalence of aspirin resistance. Turbidimetric aggregometry was also used as the gold
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standard in the comparable human study, which found that impedance aggregometry had
the highest correlation and the second highest agreement with turbidimetric aggregometry
when classifying patients as aspirin resistant. Interestingly, based on the results of
impedance aggregometry, the prevalence of aspirin resistance in humans was 18%,
similar to the 19% of dogs in our study classified as non-responsive to the anti-platelet
effects of aspirin.17 Based on our study, impedance aggregometry may provide useful
data regarding aspirin-induced platelet dysfunction in dogs when turbidimetric
aggregometry is not feasible or not available, although impedance results may vary from
turbidimetric results in some dogs on some days.
Recently, an impedance-type multiple electrode aggregometer was validated for
use in dogs, and we therefore chose to also utilize this aggregometer in our study.18 In
dogs receiving aspirin, we detected only one aspirin-responder on Day 3 using this
aggregometer, and not a single aspirin-responder on Day 7. Based on visual assessment
of the curves generated by the instrument, the multiple electrode aggregometer protocol
used in our study detected little to no aspirin-associated platelet dysfunction, a finding
that is very discrepant with the results obtained with other tests of platelet function.
Platelet aggregation was inconsistent and often demonstrated an increase in aggregation
during the course of aspirin administration. Even though the multiple electrode
aggregometer is technically very user friendly compared to the other conventional
aggregometer used in our study, our results suggest that this methodology does not
provide an accurate assessment of aspirin-associated platelet dysfunction in dogs
receiving aspirin, at lease using the protocol that we utilized. Our protocol used collagen
as an agonist to closely match the protocols used in the conventional aggregometer, and
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to match published protocols used to evaluate human aspirin responsiveness. The use of
different agonists, such as arachidonic acid, may provide a better assessment of aspirininduced platelet dysfunction using the multiple electrode aggregometer.31 Additionally,
because the multiple electrode aggregometer was only used to analyze 9 dogs, our results
did not reach a high enough power for a true evaluation of correlation with other
methods. However, based on an almost complete failure of the multiple electrode
aggregometer to detect aspirin-associated platelet dysfunction, it is highly unlikely that
the use of additional dogs would have significantly improved correlation or agreement.
Similar to previous studies in dogs15,16,22, our study confirmed that aspirinassociated platelet function could be detected utilizing a user-friendly point-of-care PFA
with a collagen/epinephrine cartridge, and that PFA closure times significantly correlated
with both turbidimetric and impedance aggregometry results. However, when
considering drug responsiveness in dogs receiving aspirin, there was poor agreement
between the point-of-care PFA and turbidimetric aggregometry. On Day 7 of aspirin
therapy, based on turbidimetric analysis, 19% of dogs were classified non-responsive
while, based PFA results, 56% of dogs were classified as non-responsive to aspirin. The
percentage of aspirin resistance in our study, based on PFA results, was somewhat greater
than a previous study using the same PFA protocol in dogs, which demonstrated an
aspirin resistance prevalence of about 33%.15 In a comparable human study, the
prevalence of aspirin resistance classified using the same point-of-care PFA and
collagen/epinephrine cartridge used in our study was 59.5% of the study population.17 In
all of these studies, the point-of-care PFA, even though it is user-friendly and often used
to clinically evaluate platelet function in human patients receiving aspirin, markedly
53

overestimates the degree of aspirin resistance compared to the gold standard turbidimetric
aggregometry, and therefore may not be the ideal instrument to use when determining if a
dog is truly aspirin resistant.
Weber et al previously described an in vitro technique that involves the
incubation of PRP with acetylsalicylic acid and analysis via turbidimetric aggregometry
to both diagnosis and categorize aspirin resistance in humans.19 In humans, aspirin
resistance can be categorized into different types based on the results of a panel of tests
including evaluation of platelet function and measurement of degree of thromboxane
suppression after patent treatment with aspirin, and evaluation of platelet function after in
vitro incubation of patient platelets with acetylsalicylic acid.19 Although, in people, the
in vitro acetylsalicylic acid incubation technique is typically performed during a period of
aspirin administration, the goal of our project was to see if this technique could also be
used to predict aspirin responsiveness prior to drug administration. In our study, canine
platelet function as measured by turbidometric aggregometry following in vitro
incubation with acetylsalicylic acid was very consistently inhibited in all dogs. As a
result, results of our in vitro acetylsalicylic acid incubation testing showed poor
agreement with conventional turbidimetric and impedance aggregometry, with multiple
electrode aggregometry, and with PFA closure times, suggesting that our particular in
vitro technique is not effective at predicting aspirin resistance in dogs. The in vitro
incubation technique used in our study was modeled on a comparable human study, and
used the same acetylsalicylic acid concentration (10μM) as previously described.19
However, since the pharmacokinetic profile of low-dose aspirin in dogs has not been
established, it is unknown if the quantity of acetylsalicylic acid used in our incubation
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study correlates with aspirin blood levels in dogs receiving low-dose therapy. One
potential explanation for the high incidence of apparent ‘aspirin-responders’ as classified
by our in vitro acetylsalicylic acid incubation study could be that the concentration of
acetylsalicylic acid used was too high, potentially mimicking the effects of higher doses
of aspirin that have been shown to consistently inhibit platelet function in most
dogs.11,16,22,26 Incubation studies using different concentrations and incubation times of
acetylsalicylic acid may provide for a more realistic assessment of low-dose aspirin
therapy.32,33 However, the concentration of acetylsalicylic acid used in our incubation
study was identical to that used in incubation studies in human patients receiving lowdose aspirin19 and, at least at higher anti-inflammatory oral doses of aspirin, the
pharmacokinetic profile of salicylate in dogs has been shown to approximate that of
humans.34-38 A pharmacokinetic study of salicylate levels in dogs receiving oral lowdose aspirin would be needed to facilitate accurate optimization of acetylsalicylic acid
concentrations in a dog species-specific aspirin incubation study. In our laboratory, the
only solution that allowed for proper dissolution of the acetylsalicylic acid was 100%
ethanol. To ensure that the ethanol itself did not alter platelet function, samples were
analyzed following incubation with pure ethanol. All dogs had strong, normal
turbidimetric platelet aggregation, suggesting that the ethanol did not markedly influence
platelet function.
Previous studies in humans have used the stable thromboxane A2 metabolite 11dehydro-thromboxane B2 as an indicator of aspirin-induced COX inhibition.9,28
Measurement of thromboxane metabolites in plasma or serum can cause artifactual
increases because platelets can be activated during blood collection, storage, or
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processing. Measurement of these metabolites in urine, in contrast, circumvents this
complication, and is therefore considered a more reliable indicator of systemic
thromboxane synthesis.9,10 A previous study in dogs has demonstrated that, compared to
the 11-dTXB2 assay used in our study, urinary 2,3-dinorTXB2 levels were a more
sensitive indicator of aspirin-induced thromboxane inhibition.26 However, although the
urine 11-dTXB2 assay used in our study is less sensitive than the 2,3-dinorTXB2 assay,
we have previously established that the 11-dTXB2 assay is still sufficiently sensitive to
detect aspirin-induced COX inhibition in dogs receiving low-dose aspirin.15 One
proposed mechanism of aspirin resistance in humans is a variable responsiveness of
platelets to thromboxane and, in some dogs, it also appears as if thromboxane may not be
a consistent or necessary platelet agonist. In fact, it has previously been shown that about
70% of canine platelets are insensitive to thromboxane stimulation due to impaired
platelet thromboxane A2 receptor-linked G proteins.39 Based on our turbidimetric
aggregometry results, 2 dogs were inconsistently classified as non-responders (platelet
inhibition on only one of the 2 days that were evaluated), despite the fact that urinary 11dTXB2-to-creatinines ratio steadily declined from Day 0 to Day 7 in both dogs.
Interestingly, 3 of the dogs that were classified as aspirin responders based on
turbidimetric aggregometry actually had an increase in urinary 11-dTXB2-to-creatinine
ratios with aspirin therapy. Our results, particularly the findings that aspirin nonresponsiveness was detected in several dogs despite documentation of suppressed
thromboxane synthesis, and that there was no correlation between turbidimetric
aggregometry and urine 11-dTXB2-to-creatinine ratios, suggest that aspirin resistance in
some dogs, as in humans, is due to more than a simple failure to suppress COX enzymes.
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Further studies using the more sensitive urinary 2,3-dinorTXB2 assay (unfortunately,
currently not commercially available) would be needed to better define the role of
thromboxane in aspirin resistance. Potential thromboxane-independent causes of aspirin
resistance in dogs, as in humans, include decreased drug bioavailability, poor
compliance, and platelet activation via alternative agonists such as ADP. Based on our
results, aspirin resistance in dogs, as in people, appears to be multifactorial, and the
precise cause may vary amongst patients.
Commonly published ‘low doses’ of aspirin for platelet inhibition in dogs range
from 0.5 mg/kg once daily to 1 mg/kg once daily.15,26,40-42 Interestingly, much higher
doses of aspirin, such as 10 mg/kg orally twice daily, have been shown to reliably inhibit
platelet function in all dogs, confirming that aspirin-associated platelet dysfunction is
highly dose-dependent. It is therefore possible that one potential cause of ‘aspirin
resistance’ in dogs receiving low (0.5 to 1 mg/kg once daily) doses of aspirin is simple
drug under dosage, and that simply increasing the dose of aspirin that is considered to be
‘low-dose’ would eliminate aspirin non-responsiveness in some dog. Further studies
would be needed to determine the dose (or dose range) of aspirin that maximizes
inhibition of thromboxane synthesis and platelet function without the undesirable effect
of also inhibiting prostacyclin synthesis.
One limitation of our study is that, by using dogs from a community-owned rather
than research population, we were unable to precisely control all aspects of the dog’s
environment. Evaluation of a wide variety of dog breeds rather than a relatively
homogenous research dog population allowed for a more clinically relevant assessment
of aspirin resistance in the general canine population. However, although not reported by
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the owners, some community-owned dogs could have potentially been exposed to nonaspirin medication. Additionally, even though it was also not reported by owners, poor
compliance could have contributed to inconsistent aspirin responses. Another limitation
of our study was that urine from each dog on each day was not collected at the same time.
Although an attempt was made to collect urine at the same time each day, some dogs
urinated prior to admission or had a minimal amount of urine in the bladder. Variation in
time of collection after aspirin administration may potentially have affected urine
thromboxane levels. Finally, our population of healthy dogs had no obvious health
problems, and the results of our study therefore may not be directly applicable to the
diseased clinic population. Further research would need to be done looking at
populations of dogs with specific disorders.
In conclusion, our study demonstrated that most, but not all, dogs respond to the
anti-platelet effects of low-dose aspirin as measured by conventional aggregometry.
Conventional impedance aggregometry results correlate with turbidimetric aggregometry
results with reasonable but not perfect agreement while, in contrast, multiple electrode
impedance aggregometer results cannot be used to establish aspirin responsiveness.
Platelet function as measured by a point-of-care PFA showed poor agreement with
conventional aggregometry, and tended to overestimate the incidence of aspirin
resistance, suggesting that this instrument may not provide a reliable measurement of
aspirin-induced platelet dysfunction in dogs. Turbidimetric aggregometry after
acetylsalicylic acid incubation using an in vitro methodology established in humans did
not predict aspirin response in dogs.
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Materials, Instruments, and Supplies
a. PFA-100®, Siemens Healthcare Diagnostics, Deerfield, IL
b. PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics, Duluth,
GA
c. Aspirin, Major Pharmaceuticals, Livonia, MI
d. PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics, Duluth,
GA
e. 3.2% sodium citrate, Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ
f. Hirudin Vacutainer tube, Verum Diagnostica GmbH, Munich, Germany
g. Chronolog 700 Whole Blood/Optical Lumi-Aggregometer, Chronolog
Corporation, Haverton, PA
h. Chronolog 700 Manual, Chronolog Corporation, Haverton, PA
i. AGGRO/LINK 8, Chronolog Corporation, Haverton, PA
j. Multiplate® Analyzer, Verum Diagnostica GmbH, Munich, Germany
k. Multiplate® Analyzer Manual, Verum Diagnostica GmbH, Munich, Germany
l. 11-dehydro-thromboxane B2 EIA kit-Monoclonal, Cayman Chemical Co, Ann
Arbor, MI
m. SpectraMax M5 Multi-Mode Microplate Reader, Molecular Devices,
Sunnyvale, California
n. ACE Alera® Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell,
NJ
o. SAS for Windows version 9.2, SAS Institute, Cary, NC, 2008
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CHAPTER III
CONCLUSION

In this study a variable rate of canine aspirin responders was identified. Using the
gold standard method of turbidimetric aggregometry, approximately 81% of dogs would
be considered to show a normal inhibition of platelet function when exposed to aspirin.
These dogs would therefore be “aspirin responders”. That leaves an additional 19% of
dogs that did not show a significant inhibition of platelet aggregation defined as >25%
reduction in maximum amplitude of aggregation.
The definition of a gold standard is that which is the best available under
reasonable conditions.1 This does not mean that it is always the best possible test in
absolute terms. Turbidimetric aggregometry has long been the gold standard in human
medicine for evaluating platelet aggregation. However, skepticism remains as to whether
this is an appropriate distinction and there remains no standardized methods for
performing this technique.2,3 The use of turbidimetric aggregometry to assess platelet
function in veterinary medicine has been extrapolated from its use in human medicine. It
remains unproven whether that this extrapolation can truly be made. When performing
our research we accepted the concept of turbidimetric as the gold standard, but the
possible exceptions to this concept cannot be completely forgotten or disregarded.
With this in mind, our research also found impedance aggregometry to have the
same percent of dogs identified as “aspirin responders” as the gold standard
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turbidimetric. The two aggregometry methods did not, however, have good agreement
and only moderate correlation. It was also noted that the two methods both classified
three dogs as non-responders, but each method identified three different dogs.
Turbidimetric aggregometry was compared with the more user friendly options
available, the Multiplate® and PFA-100. Multiplate® found all dogs to have poor
response to aspirin administration in that all dogs continued to have normal aggregation
readings even after being administered aspirin. Therefore, all dogs would be classified as
“aspirin non-responders”. This method had neither agreement nor correlation with any of
the other methods. The PFA-100 found 44% of dogs have appropriate response to aspirin
administration showing a closure time of >300 seconds on day 7. This test had poor
agreement but moderate correlation with both turbidimetric and impedance
aggregometry.
The results found with the more user friendly modalities bring into question their
ability to replace or act as a surrogate for the more traditional aggregometry methods for
the purpose of studying aspirin response. The Multiplate® does not appear to function at
all as an indicator of aspirin induced platelet dysfunction. The PFA-100 only found the
same final result as turbidimetric in 10 of 16 dogs. That means inappropriate therapy
could potentially be administered based on these results. In this setting, PFA-100 is an
unreliable method for evaluating platelet function in dogs given aspirin. It is not known
if better agreement or correlation would be seen with higher aspirin doses or when used
with other medications or conditions affecting platelet function. Further studies in this
area would be needed.
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Given the findings in this study, with the acceptance of turbidimetric as the gold
standard, there does not appear that either of the more user friendly options can replace
turbidimetric in this capacity. Furthermore, while impedance findings were similar,
discordant results also do not make it a strong option for the replacement of turbidimetric
aggregometry.
Aspirin was given for a total of 7 days with evaluation of function performed on
days 3 and 7. In multiple cases, the results on day 3 did not match those on day 7. Some
dogs progressed from a non-responder to a responder while others actually became less
aspirin responsive over time, switching from a responder to a non-responder. The
reasons for these findings are not completely known. Some dogs may have required
more time for aspirin to have complete effect such that a progressive inhibition of platelet
function was occurring. Other dogs may have become aspirin resistant due to any of a
variety of causes such as changes in thromboxane production or response, increased
platelet turnover to produce more non-aspirinated platelets, administration complications
such as poor compliance, bioavailability issues, or co-administration of other NSAIDs.
In most dogs, a final aspirin response was seen by 3 days. This may indicate that
evaluation of platelet function could be performed early on in therapy. This would
shorten the time period of inappropriate treatment if a dog was an aspirin non-responder.
Unfortunately, testing at 3 days would not necessarily prove that a non-responder would
not further progress into a responder or rule out that resistance would not develop. Our
study did not look beyond 7 days to determine if further changes in aspirin response
developed with longer term use. Further research would be needed looking at these
effects. Our study results do not allow for a recommendation of testing of platelet
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function on day 3 of aspirin administration. Testing would need to be performed after at
least 7 days of consecutive low dose aspirin administration. It would be possible that
response time would vary and perhaps be faster in dogs given a higher dose of aspirin.
Not all dogs in this study showed consistent results throughout the testing period.
A fair amount of individual variation was seen especially on day 3 but also on day 7.
Some dogs had markedly different results even between samples run simultaneously
under all the same conditions with blood coming from the same tube. These dogs may
have had one sample that showed complete suppression of aggregation and another
sample that showed normal aggregation. These dogs seemed to demonstrate a threshold
response in which some samples may have been on the verge of aggregation and were
therefore more sensitive and could be more easily tipped over into aggregation. This
finding could also suggest a dose dependant mechanism. It may be that by making a
small dose increase that this threshold response could be overcome, leading to more
consistent aggregation. Further research looking at gradual dose escalation would be
warranted to determine the optimal dose of aspirin that would inhibit platelet function
while still allowing for the production of prostacyclin. The ideal dose would still be a
low dose that could be given once daily, but would not cause any of the side effects seen
with higher anti-inflammatory aspirin doses.
One of the major goals of this study was to find a way to more easily predict
aspirin response. Unfortunately, none of the more user friendly options were consistent
enough to replace turbidimetric in standard testing. We next looked at an in vitro method
of evaluating aspirin induced platelet dysfunction. When platelet rich plasma was
incubated with 100 uM of acetylsalicylic acid we found that platelet function was
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strongly inhibited in all the dogs. A few dogs showed a very weak aggregation but still
greatly reduced from baseline. This method, therefore, did not allow for prediction of
individual aspirin response. The choice of protocol for the in vitro portion of this study
was taken from a similar study done by Weber et al, which used human patients.4 The
goal was to mimic the results of their study to see if comparable results would be
obtained. Their study found variation in turbidimetric aggregometry results in patients
given oral aspirin in combination with in vitro aspirin incubation. When also combined
with thromboxane levels, three different groups of aspirin responders were identified.
Our study did not find that differences among dogs could be found using these
techniques. Following the previous classification system discussed in vitro incubation
found all the dogs to be aspirin responders.
The findings of our study do not rule out the possibility of using in vitro aspirin
incubation to predict aspirin response. The methods we used may not be ideal for the
canine patient. The aspirin levels obtained in the in vitro testing may far exceed what is
reached in vivo. The concentration of aspirin we used may be more comparable with a
high dose aspirin administration, which could lead to more extensive platelet suppression.
It is also possible that canine platelets are more sensitive to the effects of thromboxane
such that lower doses of aspirin have more profound effects then what is seen in people.
This theory seems less likely give the fact that human patients in the Weber et al study
showed marked suppression (>95%) of thromboxane levels while the dogs in our study
showed a mean suppression of urine thromboxane levels of 49%.4 Finally, it may simply
be that the causes for aspirin resistance in dogs are different then what are seen in people.
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The ways in which aspirin resistance are evaluated and classified in people may not
extrapolate well to canine patients.
Urine thromboxane levels decreased significantly in all the dogs as a group.
When looking at the three dogs that were classified as aspirin non-responders via
turbidimetric as individuals, only 2 of the 3 dogs showed a decreased thromboxane level.
This could indicate different mechanisms were responsible for their aspirin resistance.
Dogs that did show a decreased urine thromboxane level appeared to be reacting in a
normal manner to aspirin. In other words, the aspirin was working properly but for some
reason the dogs still were not showing the anti-platelet effects that would be expected.
This could be due to variability in thromboxane receptors between individuals. One of
the dogs showed what appeared to be thromboxane independent aspirin resistance. This
would imply that aspirin did not have the expected affect on suppression of thromboxane.
This could be due to an alternative pathway formation of thromboxane or other factors
such as affects on bioavailability, compliance, increased platelet turnover, etc.
Interestingly, several dogs that were classified as aspirin responders based on
turbidimetric aggregometry results did not have a significant decrease or had an increase
in thromboxane levels during treatment. Some dogs even showed a rebound with a
decrease at day 3 followed by an increase of thromboxane on day 7. A possible cause for
this is inaccuracy with the measurement of thromboxane. It has been proposed that 2,3
dinor thromboxane B2 is a better metabolite for evaluation of aspirin response in dogs.5
However, these results could also suggest that there are different ways in which aspirin
affects platelet function. Aspirin has been shown to affect several aspects of secondary
hemostasis including thrombin formation and proposed to inhibit tissue factor synthesis.6
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It is possible that aspirin may also have additional affects on primary hemostasis not yet
determined that not only affects platelet response to aspirin but allows for different
avenues of aspirin resistance.
Ultimately the causes for aspirin resistance in dogs remains unknown and is likely
multifactorial. The causes may be similar to what is suspected in humans but other
mechanisms and causes cannot be ruled out. It may remain difficult to elucidate these
causes due to what may be extensive individual variation. With further research, it may
become possible to at least predict aspirin resistance in a global sense, even if the exact
cause remains unknown.
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